Sun Pharmaceutical Industries Ltd. plans to acquire 100% of Innovcare Lifesciences Private Limited for about ₹271.2 crore, expanding its presence in consumer healthcare and speciality products.
The transaction will be carried out entirely in cash. Sun Pharma said the deal does not involve related parties and does not require regulatory approvals.
Shares of the company rose 0.8% during Monday’s trade to an intraday high of ₹1,853.55, compared with the previous close of ₹1,837.15. Sun Pharma’s market capitalisation stood at ₹4.44 lakh crore.
Acquisition details
Mumbai-based Innovcare Lifesciences is engaged in the marketing, distribution and sale of:
- Pharmaceutical drugs
- Nutraceutical products
- Cosmeceutical products
Sun Pharma expects to complete the acquisition on or before July 31, 2026.
Once the transaction is closed, Innovcare will become a wholly owned subsidiary of Sun Pharma.
According to the company, the acquisition will help strengthen its product portfolio and expand its distribution reach.
Innovcare revenue
Innovcare has reported steady growth over the last three financial years.
Revenue
- FY26: ₹94.06 crore
- FY25: ₹86.09 crore
- FY24: ₹80.93 crore
March quarter performance
Sun Pharma reported higher revenue and profit for the quarter ended March 2026.
Revenue
- March 2026: ₹14,612 crore
- March 2025: ₹12,959 crore
- Growth: 12.76%
Net profit
- March 2026: ₹2,710 crore
- March 2025: ₹2,154 crore
Key financial metrics
The company reported:
- ROCE: 20.5%
- ROE: 16%
- Debt-to-equity ratio: 0.06
- Dividend payout ratio: 34.1%
Global business
In FY25, Sun Pharma reported revenue of more than $6.2 billion and held more than $3.1 billion in cash.
About 20% of revenue came from the Innovative Medicines business.
The company said it is the largest pharmaceutical company in India by revenue and has operations in more than 100 countries.
Company profile
Founded in 1983 and headquartered in Mumbai, Sun Pharmaceutical Industries develops and manufactures speciality medicines, branded generics, complex formulations and active pharmaceutical ingredients.
Its products are used across several therapeutic areas, including:
- Cardiology
- Neurology
- Dermatology
- Oncology
The company has expanded its presence through acquisitions and investments in research and development. It has operations across regulated markets, including the US and Europe.
TL;DR:
Sun Pharma will acquire Mumbai-based Innovcare Lifesciences for ₹271.2 crore in an all-cash transaction. The deal, expected to close by July 31, 2026, will give Sun Pharma full ownership of the company and expand its consumer healthcare presence.
AI summary:
- Sun Pharma will buy Innovcare Lifesciences for ₹271.2 crore.
- The deal is an all-cash transaction.
- Completion is expected by July 31, 2026.
- Innovcare reported FY26 revenue of ₹94.06 crore.
- Sun Pharma’s March-quarter revenue and profit increased year-on-year.
